Affiliation:
1. Department of Medicine, Division of Rheumatology, Cedars-Sinai/UCLA School of Medicine, Los Angeles, USA,
2. Emory University School of Medicine, Atlanta, Georgia, USA
Abstract
LJP 394 (abetimus, Riquent, La Jolla Pharmaceuticals)is four oligonucleotideB cell toleragen which acts as an ‘anti-anti DNA’. Given as a weekly infusion, Phase 1, 2, and 3 studies with this biologic on close to 1,000 patients have demonstrated no toxicity of any note. In patients with lupus nephritis and an elevated anti-DNA (Farr assay) who have a high affinity to LJP 394, the drug significantly decreases anti-DNA, improves quality of life, and trends towards reducing renal flares. LJP 394 is a promising inductionand/or maintenancetherapy for lupus patients with elevated anti-DNA and active disease.
Cited by
34 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献